
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер 137, С. 111260 - 111260
Опубликована: Янв. 22, 2025
Язык: Английский
Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер 137, С. 111260 - 111260
Опубликована: Янв. 22, 2025
Язык: Английский
Asian Journal of Psychiatry, Год журнала: 2025, Номер 106, С. 104426 - 104426
Опубликована: Март 5, 2025
Язык: Английский
Процитировано
0Journal of Education Health and Sport, Год журнала: 2025, Номер 77, С. 56620 - 56620
Опубликована: Янв. 14, 2025
MDMA or 3,4- methylenedioxymethamphetamine is a psychoactive substance, exhibiting mild hallucinogenic properties, that became widely known as recreational party drug. However, its ability in helping individuals access deeply rooted emotions has prompted significant interest potential applications within clinical practice. MDMA’s mechanism of action involves increasing the release serotonin, dopamine and oxytocin. This process enhances neuroplasticity, fosters empathy aids trauma processing fear extinction. study aims to explore uses medicine, particularly treating mental illnesses. The article was developed using data from „PubMed” „Google Scholar” databases, with particular emphasis on articles published after 2021. When combined psychotherapy, offers therapeutic benefits, especially for patients resistant conventional treatments. Existing research primarily highlights effectiveness managing post traumatic stress disorder (PTSD) anxiety disorders, emerging evidence suggesting benefits conditions like depression eating disorder. While use poses risks, controlled environment demonstrates favourable safety profile. Despite highly promising results MDMA- assisted therapy so far, additional crucial enable this drug revolutionise future treatment methods.
Язык: Английский
Процитировано
0Progress in Neuro-Psychopharmacology and Biological Psychiatry, Год журнала: 2025, Номер 137, С. 111260 - 111260
Опубликована: Янв. 22, 2025
Язык: Английский
Процитировано
0